First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays.

Commercial immunoassays for measuring Aβ₄₂ in cerebrospinal fluid often produce inconsistent results across different platforms. Prior research has shown that diagnostic variability can hinder accurate diagnosis of neurodegenerative diseases like Alzheimer's. This gap motivated the development of standardized reference materials to improve assay comparability. Existing methods lacked traceable calibration standards, limiting the ability to harmonize diagnostic measurements. No prior work had resolved how to reduce inter-assay bias while maintaining accuracy. The absence of certified reference materials created uncertainty about diagnostic reliability. This uncertainty drove the need for a solution that could align commercial immunoassays. The field required a way to ensure consistent results across different diagnostic platforms. This paper addresses that need by introducing a new calibration approach.

The aim of this work is to introduce the first certified reference materials for Aβ₄₂ in human cerebrospinal fluid. These materials are intended to improve diagnostic consistency across immunoassays. The study focuses on reducing inter-assay bias by providing a traceable calibration standard. It addresses the problem of diagnostic variability in Aβ₄₂ measurements. The motivation stems from the need for reliable biomarker testing in neurodegenerative diseases. The researchers propose using isotope dilution mass spectrometry to characterize the reference materials. This approach allows for precise mass concentration certification. The goal is to enable harmonized diagnostic results across different commercial immunoassays.

Three certified reference materials were prepared at varying concentration levels. Isotope dilution mass spectrometry was used to determine Aβ₄₂ mass concentrations. The CRMs were assigned specific values with expanded uncertainties. Roche, EUROIMMUN, and Fujirebio participated in the re-calibration process. Each company tested the CRMs with their immunoassays before and after re-calibration. Pearson's correlation coefficient was calculated to assess inter-assay agreement. Expanded uncertainties were reported at a confidence level of k = 2. The study used a comparative approach to evaluate assay performance before and after calibration.

The CRMs were assigned mass concentrations of 0.45, 0.72, and 1.22 μg/L with uncertainties of 0.07, 0.11, and 0.18 μg/L, respectively. Before re-calibration, inter-assay correlation was strong (Pearson’s r > 0.97). However, large biases were observed between commercial immunoassays. After re-calibration, the between-assay bias was reduced to less than 5%. This reduction suggests improved diagnostic consistency across platforms. The results indicate that the CRMs can harmonize Aβ₄₂ measurements. The study found that isotope dilution mass spectrometry provided accurate certification values. The findings support the use of these CRMs for diagnostic standardization.

The authors propose that the CRMs can ensure equivalent diagnostic results across immunoassays. They suggest that re-calibration using these materials reduces inter-assay bias to below 5%. The study indicates that certified reference materials improve diagnostic comparability. The findings support the use of isotope dilution mass spectrometry for accurate calibration. The authors suggest that these materials can be used to standardize Aβ₄₂ measurements. They propose that the CRMs may help improve diagnostic accuracy in neurodegenerative diseases. The study suggests that harmonized diagnostic results may improve patient care. The authors suggest that these materials may support more reliable biomarker testing.